MedTrace Logo

The Influence of the Femoral Nerve Block on Quadriceps Strength

NCT01111513 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2012-12-20

No results posted yet for this study

Summary

Total knee replacement is a frequent procedure in Québec's hospitals and the muscular strength of the quadriceps is the best indicator of the patient's functional recovery post surgery. Thus, the importance of the patient's recovery leads to the evaluation of the influence of the femoral nerve block on the muscle strength.

The purpose of the study is to compare the short term and long term recuperation of the quadriceps' motor strength of after a total knee arthroplasty using different types of analgesics such as the continuous femoral nerve block, the single dose femoral nerve block and the systemic analgesic, a patient controlled analgesic pump.

Conditions

  • Total Knee Arthroplasty

Interventions

DRUG

48-hour ropivacaine infusions

Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.

DRUG

Single dose ropivacaine

Patients receive 20 ml of ropivacaine 0.5% pre-operation

DRUG

Patient controlled analgesics

Patient controlled analgesics alone, no femoral block

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Hopital de l'Enfant-Jesus

    lead OTHER

Principal Investigators

  • Stéphane Pelet, MD, PhD · Hôpital Enfant-Jésus

  • Michèle Angers, PhD · Hôpital Enfant-Jésus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2011-03-31
Completion
2012-02-29

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01111513 on ClinicalTrials.gov